Susan Eylward Biography and Net Worth

General Counsel of Imunon

Susan Eylward is the General Counsel of Imunon.

What is Susan Eylward's net worth?: The estimated net worth of Susan Eylward is at least $3.30 thousand as of August 17th, 2026. Eylward owns 2,896 shares of Imunon stock worth more than $3,301 as of October 7th. This net worth estimate does not reflect any other assets that Eylward may own. Learn More about Susan Eylward's net worth.
How do I contact Susan Eylward?: The corporate mailing address for Eylward and other Imunon executives is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. Imunon can also be reached via phone at (609) 896-9100 and via email at [email protected]. Learn More on Susan Eylward's contact information.
Has Susan Eylward been buying or selling shares of Imunon?: Susan Eylward has not been actively trading shares of Imunon in the last ninety days. Most recently, Susan Eylward sold 2,449 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1.63, for a transaction totalling $3,991.87. Following the completion of the sale, the general counsel now directly owns 2,896 shares of the company's stock, valued at $4,720.48. Learn More on Susan Eylward's trading history.
Are insiders buying or selling shares of Imunon?: During the last twelve months, insiders at the sold shares 5 times. They sold a total of 19,860 shares worth more than $34,187.84. The most recent insider tranaction occured on August, 17th when General Counsel Susan Eylward sold 2,449 shares worth more than $3,991.87. Insiders at Imunon own 2.8% of the company. Learn More about insider trades at Imunon.
Information on this page was last updated on 8/17/2026.

Susan Eylward Insider Trading History at Imunon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/17/2026	Sell	2,449	$1.63	$3,991.87	2,896
8/3/2026	Sell	2,541	$1.57	$3,989.37	2,896
7/20/2026	Sell	2,150	$1.78	$3,827.00	2,896
7/6/2026	Sell	920	$1.88	$1,729.60	2,896
6/29/2026	Sell	11,800	$1.75	$20,650.00	2,896

Susan Eylward Buying and Selling Activity at Imunon

Imunon Company Overview

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Today's Range

Now: $1.14

$1.10

$1.16

50 Day Range

MA: $1.51

$1.12

$1.67

2 Week Range

Now: $1.14

$1.10

$5.40

Volume

106,391 shs

Average Volume

99,402 shs

Market Capitalization

$6.40 million

P/E Ratio

N/A

Dividend Yield